Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 10/20 | 0.67 |
| ▸ | KDR | P35968 | 7/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 3/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265806 | 0.89 | TEK (0.78) | TEKKDRPOLBBRAFRAF1 | |
| SCHEMBL12895344 | 0.89 | TEK (0.81) | TEKKDRLCKMAPK14JAK3 | |
| SCHEMBL1265112 | 0.84 | TEK (0.76) | TEKKDRLCKMAPK14JAK3 | |
| SCHEMBL1265260 | 0.84 | TEK (0.78) | TEKKDRLCKMAPK14JAK3 | |
| SCHEMBL1267851 | 0.83 | TEK (0.68) | TEKKDR | |
| SCHEMBL2297112 | 0.80 | TEK (1.00) | TEKKDRPOLBALDH1A1GAA | |
| SCHEMBL1265089 | 0.80 | KDR (0.70) | TEKKDRBRAFLCKMAPK14 | |
| SCHEMBL1264994 | 0.80 | TEK (1.00) | TEKKDRLCKMAPK14 | |
| SCHEMBL1264864 | 0.79 | TEK (0.84) | TEKKDRLCKMAPK14 | |
| SCHEMBL1264376 | 0.79 | TEK (0.74) | TEKKDRLCKMAPK14JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | claimed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | claimed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | claimed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | TEK 215/4885KDR 58/4885POLB 1679/4885 |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | GRK4, MAP4K5, GRK5 | TEK 145/4885KDR 42/4885POLB 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.